First Human Monoclonal Thyroid-Stimulating Autoantibody Isolated

[Guest guest]

Focus On... ADHD ALLHAT Alzheimer's Disease APN Business & Law Asthma Biologic Therapies Bioterrorism Bipolar Disorder Breast Cancer Depression Erectile Dysfunction Genital Herpes GERD Geriatric Care Heart Failure Heart Failure: CRT Hepatitis C HIPAA Home Defib in SCA Hyperlipidemia IBS InfluenZone Insulin Pump Tx Kidney Disease Lung Cancer Menopause Micro Complications Multiple Sclerosis Nutrition Osteoporosis Ovarian Cancer Pain Management Pancreatic Cancer Patient Safety Rheum Arthritis Schizophrenia Secondary Anemia Sepsis Serious Mental Ill Sports Medicine UTI-Zone Weight Management ================= Related Topics ================= Disaster & Trauma Dyslipidemia & HIV Health Diversity Hospice Care

Welcome, W Webb osterloh

July 11, 2003

First Human Monoclonal Thyroid-Stimulating Autoantibody Isolated

NEW YORK (Reuters Health) Jul 10 - For the first time, a human monoclonal autoantibody (MAb) to thyroid stimulating hormone receptor (TSHR) has been isolated. This finding could lead to a raft of diagnostic and therapeutic agents for patients with Grave's disease and other hormone disorders, researchers report in the July 12th issue of The Lancet.

Dr. Bernard Rees , of FIRS Laboratories in Cardiff, UK, and colleagues isolated the MAb from lymphocytes of a man with hyperthyroidism due to Graves' disease and type 1 diabetes mellitus. After screening 16,500 hybridomas, they isolated a single colony producing high concentrations of TSHR autoantibody of the IgG1 subclass.

Assays showed that the MAb was about 3000 times more active than donor serum IgG in its ability to inhibit TSH binding and stimulate cyclic AMP. Since its isolation, Dr. 's group has continued to produce about 10 mg of IgG per liter of culture medium for more than 9 months.

If the existence of the MAb is confirmed, an assay for Graves' disease could replace other, less specific antibody tests and lead to better understanding of the disorder, suggests Dr. Colin M. Dayan, of the Royal Bristol Infirmary, in an accompanying editorial.

"Understanding of the biology of glycoprotein-hormone receptors may lead to new small-molecule agonists and antagonists not only for thyroid disease but also for hypogonadism and infertility (via the closely related receptors for luteinising and follicle-stimulating hormones)," Dr. Dayan writes. Furthermore, it could lead to a rapid initial treatment for thyrotoxicosis or an agent to enhance iodine-131 uptake in thyroid cancers.

Lancet 2003;362:92-93,126-128.

Reuters Health Information 2003. © 2003 Reuters Ltd. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Clinical articles on this topic

Advanced Search

Medscape

DrugInfo

MEDLINE

About Medscape

Privacy & Ethics

Terms of Use

Help

WebMD Health

All material on this website is protected by copyright, Copyright © 1994-2003 by Medscape. This website also contains material copyrighted by 3rd parties. Medscape requires 4.x browsers or better from Netscape or Microsoft.

[Guest guest]

This is Soooooo exciting!

First Human Monoclonal Thyroid-Stimulating Autoantibody Isolated

Focus On... ADHD ALLHAT Alzheimer's Disease APN Business & Law Asthma Biologic Therapies Bioterrorism Bipolar Disorder Breast Cancer Depression Erectile Dysfunction Genital Herpes GERD Geriatric Care Heart Failure Heart Failure: CRT Hepatitis C HIPAA Home Defib in SCA Hyperlipidemia IBS InfluenZone Insulin Pump Tx Kidney Disease Lung Cancer Menopause Micro Complications Multiple Sclerosis Nutrition Osteoporosis Ovarian Cancer Pain Management Pancreatic Cancer Patient Safety Rheum Arthritis Schizophrenia Secondary Anemia Sepsis Serious Mental Ill Sports Medicine UTI-Zone Weight Management ================= Related Topics ================= Disaster & Trauma Dyslipidemia & HIV Health Diversity Hospice Care

Welcome, W Webb osterloh

July 11, 2003

First Human Monoclonal Thyroid-Stimulating Autoantibody Isolated

NEW YORK (Reuters Health) Jul 10 - For the first time, a human monoclonal autoantibody (MAb) to thyroid stimulating hormone receptor (TSHR) has been isolated. This finding could lead to a raft of diagnostic and therapeutic agents for patients with Grave's disease and other hormone disorders, researchers report in the July 12th issue of The Lancet.

Dr. Bernard Rees , of FIRS Laboratories in Cardiff, UK, and colleagues isolated the MAb from lymphocytes of a man with hyperthyroidism due to Graves' disease and type 1 diabetes mellitus. After screening 16,500 hybridomas, they isolated a single colony producing high concentrations of TSHR autoantibody of the IgG1 subclass.

Assays showed that the MAb was about 3000 times more active than donor serum IgG in its ability to inhibit TSH binding and stimulate cyclic AMP. Since its isolation, Dr. 's group has continued to produce about 10 mg of IgG per liter of culture medium for more than 9 months.

If the existence of the MAb is confirmed, an assay for Graves' disease could replace other, less specific antibody tests and lead to better understanding of the disorder, suggests Dr. Colin M. Dayan, of the Royal Bristol Infirmary, in an accompanying editorial.

"Understanding of the biology of glycoprotein-hormone receptors may lead to new small-molecule agonists and antagonists not only for thyroid disease but also for hypogonadism and infertility (via the closely related receptors for luteinising and follicle-stimulating hormones)," Dr. Dayan writes. Furthermore, it could lead to a rapid initial treatment for thyrotoxicosis or an agent to enhance iodine-131 uptake in thyroid cancers.

Lancet 2003;362:92-93,126-128.

Reuters Health Information 2003. © 2003 Reuters Ltd. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Clinical articles on this topic

Advanced Search

Medscape

DrugInfo

MEDLINE

About Medscape

Privacy & Ethics

Terms of Use

Help

WebMD Health

All material on this website is protected by copyright, Copyright © 1994-2003 by Medscape. This website also contains material copyrighted by 3rd parties. Medscape requires 4.x browsers or better from Netscape or Microsoft.